Free tool
FAERS Monitor: Eucrisa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207695 or its brand name (Eucrisa, Crisaborole). Reports on generic versions are filed under their own applications.
Reports
9,605
Serious
734
8% of reports
Hospitalization
158
Death reported
25
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,995
- application site pain1,417
- burning sensation987
- off label use759
- condition aggravated711
- pruritus662
- rash622
- pain530
- eczema469
- dermatitis atopic455
- erythema376
- product use in unapproved indication341
- dry skin273
- drug hypersensitivity262
- drug ineffective for unapproved indication243
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1,288 |
| 2018 | 2,074 |
| 2019 | 1,981 |
| 2020 | 1,051 |
| 2021 | 497 |
| 2022 | 941 |
| 2023 | 675 |
| 2024 | 528 |
| 2025 | 371 |
| 2026 | 197 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site painSignal | 1,417 | 150.5 | 143.1 | 196,937 |
| burning sensationSignal | 987 | 31.3 | 29.4 | 28,561 |
| eczemaSignal | 469 | 19.8 | 18.1 | 8,296 |
| dermatitis atopicSignal | 455 | 19.1 | 17.4 | 7,716 |
| drug ineffective for unapproved indicationSignal | 243 | 9.7 | 8.6 | 1,892 |
| condition aggravatedSignal | 711 | 5.1 | 4.8 | 2,389 |
| dry skinSignal | 273 | 4.5 | 4.0 | 739 |
| erythemaSignal | 376 | 4.0 | 3.6 | 854 |
| pruritusSignal | 662 | 3.8 | 3.5 | 1,372 |
| drug ineffectiveSignal | 1,995 | 3.3 | 3.2 | 3,440 |
| rashSignal | 622 | 3.1 | 2.9 | 916 |
| product use in unapproved indicationSignal | 341 | 3.0 | 2.7 | 462 |
| drug hypersensitivitySignal | 262 | 3.0 | 2.6 | 342 |
| off label use | 759 | 1.9 | 1.8 | 336 |
| pain | 530 | 1.9 | 1.7 | 228 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.